Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamnorzatinib (ONO-7475) alone and with nivolumab in advanced solid tumors
NCT03730337Phase 1Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Oct 2018
- Primary completion
- Jun 2021
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of ONO-7475 in solid tumor (2 arms), sponsored by Ono Pharmaceutical. Primary endpoints: Number of participants with dose-limiting toxicities at 28 days and Incidence and severity of adverse events at 1 year. Started Oct 2018; status: completed.
02
Drugs
ONO-7475
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03730337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03730337.